Arrowhead Pharmaceuticals falls on earnings miss
Arrowhead Pharmaceuticals (ARWR) reported fiscal 2026 earnings missing estimates, with a $5.11 loss per share and $450.82M revenue. Despite the miss, the company highlighted growth in REDEMPLO prescriptions and FDA progress for plozasiran. ARWR stock fell 2.4% in after-hours trading.
How this was made
The 30-second read
Why it matters
The earnings miss underscores execution challenges but the company retains significant cash and a new senior secured loan, which may mitigate immediate liquidity concerns.
Market read
ARWR's earnings miss drives short‑term downside pressure; broader biotech sentiment may be modestly affected.
What to watch
Strong cash position ($1.19 bn) and new credit facility could support longer‑term development despite short‑term earnings disappointment.
Background
Arrowhead Pharmaceuticals is a biotech focused on RNAi therapeutics, with its lead product REDEMPLO for familial chylomicronemia syndrome and a pipeline candidate plozasiran.
Ticker impact
Arrowhead Pharmaceuticals reported FY 2026 adjusted loss of $5.11 per share and revenue miss, causing a 2.4% after‑hours decline.
downward pressure as investors price in weaker-than-expected results and higher loss per share.
The disclosed loss and revenue shortfall are new primary data; the stock already fell 2.4% after hours, indicating immediate negative sentiment.
Market effects
Biotech sector may see modest pullback as earnings miss highlights execution risk.
U.S. biotech stocks could face short‑term weakness.
Limited; primarily affects ARWR and peers.
Counterpoint
If the commercial progress of REDEMPLO and upcoming FDA review for plozasiran translate into future revenue, the miss may be temporary.
Key entities
- companyArrowhead Pharmaceuticals
Biotech firm reporting FY 2026 results.
- executiveChristopher Anzalone
President and CEO of Arrowhead.
